Form 4: PennyMac CFO Exercises Options, Sells Shares
Insider Transaction Report
PennyMac Financial Services CFO Daniel Stanley Perotti executed pre-planned transactions, exercising stock options and selling an equal number of shares for a significant profit.
Summary
- Daniel Stanley Perotti, Chief Financial Officer of PennyMac Financial Services, Inc. (PFSI), engaged in transactions on October 22, 2025, under a Rule 10b5-1 trading plan.
- Exercised nonstatutory stock options to acquire a total of 13,110 shares of Common Stock.
- Acquired 4,763 shares at an exercise price of $11.28 per share.
- Acquired 8,347 shares at an exercise price of $18.05 per share.
- Disposed of a total of 13,110 shares of Common Stock through multiple sales transactions.
- Sale prices ranged from a weighted average of $130.00 to $134.00 per share.
- Following these transactions, Mr. Perotti directly beneficially owns 9,964 shares, consisting of restricted stock units.
- Mr. Perotti indirectly beneficially owns 225,250 shares through The Perotti Family Trust.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While there is insider selling, it's a pre-planned exercise of options for profit realization, which is a normal part of executive compensation. The insider retains significant indirect ownership, and the transactions reflect a profitable outcome for the executive, which can be seen as a positive sign of past company performance.
Positives
- The CFO realized significant profits by exercising stock options at low strike prices ($11.28 and $18.05) and selling the shares at substantially higher market prices (averaging over $130 per share).
- The transactions were conducted under a Rule 10b5-1 plan, indicating pre-scheduled and not reactive selling.
- The CFO maintains a substantial indirect beneficial ownership of 225,250 shares through The Perotti Family Trust, demonstrating continued alignment with shareholder interests.
Negatives
- The direct beneficial ownership of common stock decreased by 13,110 shares as a result of the sales, although this was offset by the exercise of options.
Risks
- While these transactions were pre-planned, significant insider selling, even for profit realization, can sometimes be misinterpreted by the market and potentially lead to negative sentiment or scrutiny regarding management's view on future company performance.
Future Outlook
The filing primarily details past insider transactions and does not provide forward-looking statements or guidance on the company's future performance or strategic direction. However, it does outline future vesting schedules for various stock options, indicating continued long-term equity incentives for the CFO.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity and does not contain information directly related to broader industry trends or competitive landscape. It reflects standard executive compensation practices involving stock options and their exercise/sale.
Comparison to Industry Standards
- The exercise of stock options and subsequent sale of shares is a common practice for executives to monetize their equity compensation, particularly when executed under a Rule 10b5-1 trading plan, which is an industry standard for managing insider transactions to avoid accusations of trading on material non-public information.
- The significant difference between the exercise prices ($11.28, $18.05) and sale prices (averaging over $130) indicates a substantial gain for the executive, which is typical for long-held, in-the-money options in a company with appreciating stock value.
Stakeholder Impact
- Shareholders: The transactions represent a CFO monetizing equity compensation, which is a common practice. The pre-planned nature (10b5-1) mitigates concerns about opportunistic selling. The retained indirect ownership suggests continued alignment.
- Employees: No direct impact mentioned.
Next Steps
- Remaining nonstatutory stock options will continue to vest according to their schedules, subject to the Reporting Person's continued service. Key future vesting dates include:
- February 24, 2026 (for 12,862 shares option)
- March 1, 2026 (for 12,510 shares option)
- February 14, 2026 (for 12,529 shares option)
- March 1, 2027 (for 12,510 shares option)
- February 14, 2027 (for 12,529 shares option)
- February 14, 2028 (for 12,529 shares option)
Key Dates
| Date | Description |
|---|---|
| 2017-03-07 | Date exercisable for a nonstatutory stock option to purchase 4,763 shares at $11.28. |
| 2018-03-06 | Date exercisable for a nonstatutory stock option to purchase 8,347 shares at $18.05. |
| 2019-03-09 | Date exercisable for a nonstatutory stock option to purchase 17,204 shares at $24.40. |
| 2020-03-15 | Date exercisable for a nonstatutory stock option to purchase 18,098 shares at $22.92. |
| 2020-12-14 | Date exercisable for a nonstatutory stock option to purchase 13,506 shares at $59.68, also the first lapse of transfer restrictions. |
| 2021-02-26 | Date exercisable for a nonstatutory stock option to purchase 23,105 shares at $35.03. |
| 2022-02-25 | Date exercisable for a nonstatutory stock option to purchase 12,935 shares at $58.85. |
| 2023-02-23 | Date exercisable for a nonstatutory stock option to purchase 35,792 shares at $57.10. |
| 2024-02-24 | Date exercisable for a nonstatutory stock option to purchase 12,862 shares at $60.74. |
| 2025-03-01 | Date exercisable for a nonstatutory stock option to purchase 12,510 shares at $84.93. |
| 2025-10-22 | Date of reported stock option exercises and share sales by the CFO. |
| 2026-02-14 | Date exercisable for a nonstatutory stock option to purchase 12,529 shares at $101.76. |
| 2026-03-06 | Expiration date for the nonstatutory stock option with an exercise price of $11.28. |
| 2027-03-05 | Expiration date for the nonstatutory stock option with an exercise price of $18.05. |
| 2028-03-08 | Expiration date for the nonstatutory stock option with an exercise price of $24.40. |
| 2029-03-14 | Expiration date for the nonstatutory stock option with an exercise price of $22.92. |
| 2030-02-25 | Expiration date for the nonstatutory stock option with an exercise price of $35.03. |
| 2030-12-13 | Expiration date for the nonstatutory stock option with an exercise price of $59.68. |
| 2031-02-24 | Expiration date for the nonstatutory stock option with an exercise price of $58.85. |
| 2032-02-22 | Expiration date for the nonstatutory stock option with an exercise price of $57.10. |
| 2033-02-23 | Expiration date for the nonstatutory stock option with an exercise price of $60.74. |
| 2034-02-28 | Expiration date for the nonstatutory stock option with an exercise price of $84.93. |
| 2035-02-13 | Expiration date for the nonstatutory stock option with an exercise price of $101.76. |
Recommendation
holdThis Form 4 filing details routine, pre-planned insider transactions (exercise of options and subsequent sale of shares for profit) by the CFO. While the sale reduces direct holdings, it's a common compensation event and the insider retains substantial indirect ownership. The filing does not contain new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation based solely on this report. Investors should 'hold' and consider this a normal course of business for executive compensation.
Keywords
PennyMac Financial Services, PFSI, Insider Trading, Form 4, Stock Options, CFO, Daniel Stanley Perotti, Equity Compensation, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.